Skip to main content
Richard Pazdur, MD, Oncology, Bethesda, MD

RichardPazdurMD

Oncology • Bethesda, MD

Director, Office of Hedmatology and Oncology Drug Products, U.S. FDA

Join to view full profile

Dr. Pazdur is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Pazdur's full profile

Already have an account?

  • Office

    10202 Addison Ct
    Bethesda, MD 20817
    Phone+1 301-530-7635

Education & Training

  • University of Chicago
    University of ChicagoFellowship, Hematology and Medical Oncology, 1981 - 1982
  • Rush University Medical Center
    Rush University Medical CenterFellowship, Hematology and Medical Oncology, 1979 - 1981
  • Loyola University Medical Center
    Loyola University Medical CenterResidency, Internal Medicine, 1976 - 1979
  • Loyola University Chicago Stritch School of Medicine
    Loyola University Chicago Stritch School of MedicineClass of 1976

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 2003 - 2025
  • TX State Medical License
    TX State Medical License 1988 - 2014
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Journal Articles

  • Contribution of Early Clinical Benefit End Points to Decreased Lung Cancer Mortality Rates  
    Richard Pazdur, MD, JAMA Oncology
  • Analysis of Time to Treatment Discontinuation of Targeted Therapy, Immunotherapy, and Chemotherapy in Clinical Trials of Patients with Non-Small Cell Lung Cancer  
    G R Oxnard, G M Blumenthal, P G Kluetz, R Pazdur, Annals of Oncology
  • Metastasis-Free Survival — A New End Point in Prostate Cancer Trials  
    Richard Pazdur, MD, The New England Journal of Medicine

Abstracts/Posters

  • US Food and Drug Administration Support for Oncology Drug Development During COVID-19
    Richard Pazdur, MD, JAMA Oncology, Orlando, FL, 12/8/2019

Authored Content

  • How to Get the Dose RightApril 2022

Press Mentions

  • FDA Panel Votes for Limits on Gastric, Esophageal Cancer Immunotherapy
    FDA Panel Votes for Limits on Gastric, Esophageal Cancer ImmunotherapySeptember 30th, 2024
  • FDA Highlights Concerns over International Cancer Trials in Draft Guidance
    FDA Highlights Concerns over International Cancer Trials in Draft GuidanceSeptember 24th, 2024
  • Multiregional Clinical Trial Data on FDA Watch for U.S. Applicability
    Multiregional Clinical Trial Data on FDA Watch for U.S. ApplicabilitySeptember 16th, 2024
  • Join now to see all

Professional Memberships

Dr. Richard Pazdur, Dr. Richard Pazdur, MD, Dr. R Pazdur